chufangao/CTO huggingface dataset:
Clinical trial NCT04590781: Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer
Official title: A Phase 1b/2 Multiple-Dose Study to Evaluate the Safety and Efficacy of XmAb18087 ± Pembrolizumab in Subjects With Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer (DUET-1-02) Protocol
Sponsor: Xencor, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The study has been terminated early by the sponsor due to business decision.
Enrollment: 4.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-05-10
Primary completion date: 2022-03-24
Completion date: 2022-03-24
Baseline population: All participants who received at least 1 dose of XmAb18087.
Limitations and caveats: Study was terminated by the sponsor and only 2 participants each were enrolled in Parts A and C. No participants were enrolled for Part B. Data were not collected for the prespecified analyses of efficacy, pharmacokinetics, and immunogenicity outcome measures.
Plan to share individual participant data: NO
Clinical trial NCT02748798: Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders
Official title: Developing Optimal Parameters for Hyperpolarized Noble Gas (3He and 129Xe) and Inert Fluorinated Gas Magnetic Resonance Imaging of Lung Disorders
Sponsor: Thunder Bay Regional Health Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Funding is no longer available due to the failure to enroll the target number of participants within the required timeframe.
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-10
Primary completion date: 2021-10-16
Completion date: 2021-10-16
Clinical trial NCT03573336: Assess Safety and Efficacy of Vilaprisan in Subjects With Endometriosis
Official title: A Randomized, Double-blind, Parallel-group, Multicenter Phase 2b Study to Assess the Efficacy and Safety of Two Different Doses of Vilaprisan (BAY1002670) Versus Placebo in Women With Symptomatic Endometriosis
Acronym: VILLENDO
Sponsor: Bayer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to a change in the development program, the study was closed prematurely.
Enrollment: 8.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-07-04
Primary completion date: 2019-03-18
Completion date: 2020-11-26
Limitations and caveats: No inferential statistical analysis was performed due to a small population.
Plan to share individual participant data: NO
IPD sharing description: Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA Principles for responsible clinical trial data sharing. This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Clinical trial NCT04541173: Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Official title: A Randomized Phase II Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Sponsor: Hoosier Cancer Research Network (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to slow accrual.
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-30
Primary completion date: 2023-06-18
Completion date: 2023-06-30
Plan to share individual participant data: NO
Clinical trial NCT04756531: STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS
Official title: A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO CONTROLLED, SINGLE- AND MULTIPLE-DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF PF 07321332 IN HEALTHY ADULT PARTICIPANTS
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 70.0 (ACTUAL)
Number of arms: 6.0
Start date: 2021-02-11
Primary completion date: 2021-09-01
Completion date: 2021-09-01
Baseline population: The baseline analysis population included all participants enrolled in the study.
Plan to share individual participant data: NO
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT03942211: A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Participants With Sarcoidosis-Associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag.
Acronym: SPHINX
Sponsor: Actelion (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The sponsor decided to prematurely terminate the study due to the lower-than-expected recruitment rate
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-02-26
Primary completion date: 2023-04-19
Completion date: 2023-04-19
Limitations and caveats: All planned efficacy analyses could not be performed due to early termination of study.
Plan to share individual participant data: YES
IPD sharing description: Actelion is a Janssen pharmaceutical company of Johnson \& Johnson. The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials\\transparency.~As noted on this site, requests for access to the study data can be submitted through Yale open Access (YODA) Project site at yoda.yale.edu
Clinical trial NCT03380130: A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC
Official title: A Multicenter, Open-label, Single-arm Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT Using SIR-Spheres for the Treatment of Patients With HepatoCellular Carcinoma That Are Candidates for Locoregional Therapies
Acronym: NASIR-HCC
Sponsor: Clinica Universidad de Navarra, Universidad de Navarra (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 41.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-09-11
Primary completion date: 2020-03-01
Completion date: 2020-11-04
Plan to share individual participant data: NO
Clinical trial NCT05796765: Phase 2B Micronized DHACM vs. Saline in the Treatment of Knee Osteoarthritis
Official title: A Phase 2B, Prospective, Double-Blind, Randomized Controlled Trial of the Micronized DHACM Injectable Product Compared to Saline Placebo Injection for the Treatment of Osteoarthritis of the Knee
Sponsor: MiMedx Group, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study discontinued early by Sponsor
Enrollment: 43.0 (ACTUAL)
Number of arms: 3.0
Start date: 2023-03-24
Primary completion date: 2023-12-15
Completion date: 2023-12-15
Plan to share individual participant data: NO
Clinical trial NCT05371275: Phase II Safety Single-arm Study of CDK4/6 Inhibition With Palbociclib in Hospitalized, Moderate COVID-19 Cases to Prevent Thromboinflammation
Official title: Phase II Safety Single-arm Study of CDK4/6 Inhibition With Palbociclib in Hospitalized, Moderate COVID-19 Cases to Prevent Thromboinflammation
Acronym: CDK6COV
Sponsor: biotx.ai GmbH (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Study was withdrawn due to challenges in patient enrollment
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-04-21
Primary completion date: 2022-10-31
Completion date: 2022-12-31
Clinical trial NCT04588948: A Pharmacokinetic stuDy of intRavitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Diabetic Macular Edema
Official title: A Pharmacokinetic Study of Intravitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Diabetic Macular Edema
Acronym: DRAW-2
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Study did not proceed due to funding issues.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-31
Primary completion date: 2021-06-30
Completion date: 2021-12-31
Plan to share individual participant data: NO
Clinical trial NCT00819221: AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours
Official title: A Phase I, Open Label, Multicenter Study to Assess the Safety, Tolerability and Pharmacology of AZD2281 in Combination With Liposomal Doxorubicin (Caelyx®) in Patients With Advanced Solid Tumors
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Enrollment: 44.0 (ACTUAL)
Number of arms: 1.0
Start date: 2009-01-05
Primary completion date: 2011-11-30
Completion date: 2021-12-22
Clinical trial NCT03227029: Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age
Official title: Randomized Phase I Study of the Infectivity, Safety, and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 65.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-09-22
Primary completion date: 2019-12-19
Completion date: 2020-10-01
Baseline population: Baseline analysis population was participants who received inoculation and were followed on study past Day 0.
Clinical trial NCT02492711: Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Official title: A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Acronym: SOPHIA
Sponsor: MacroGenics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 624.0 (ACTUAL)
Number of arms: 3.0
Start date: 2015-08-24
Primary completion date: 2021-08-11
Completion date: 2022-06-14
Plan to share individual participant data: NO
Clinical trial NCT03813979: Pharmacokinetics of Single-dose Dolutegravir in HIV-seronegative Subjects With Severe Hepatic Impairment Compared to Matched Controls.
Official title: Pharmacokinetics of Single-dose Dolutegravir in HIV-seronegative Subjects With Severe Hepatic Impairment Compared to Matched Controls.
Acronym: POLO
Sponsor: Radboud University Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: difficult recruitment and delay due to COVID19
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-15
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Clinical trial NCT02664441: Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity
Official title: Glucagon-Like Peptide-1 Agonist Effects on Energy Balance in Hypothalamic Obesity
Acronym: ECHO
Sponsor: Seattle Children's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 42.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-03-31
Primary completion date: 2020-03-16
Completion date: 2020-07-31
Plan to share individual participant data: NO
Clinical trial NCT03998033: Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma
Official title: An Open-Label, Dose Escalation, Multi-Center Phase I/II Research Trial to Assess the Safety of ET140202 T Cells and Determine the Recommended Phase II Dose (RP2D) in Adults With Advanced Hepatocellular Carcinoma (HCC)
Acronym: ET-109
Sponsor: Eureka Therapeutics Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Reallocation of resources to new HCC study.
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-05-30
Primary completion date: 2020-12-31
Completion date: 2020-12-31
Plan to share individual participant data: NO
Clinical trial NCT04083170: Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
Official title: Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells to Facilitate the Engraftment of a Single CCR5Δ32 Homozygous or Heterozygous Cord Blood Unit in Patients With HIV and Hematological Malignancies
Sponsor: Fred Hutchinson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The federal funding period ended. The study was originally intended to be multi-site but was only conducted at the lead site. Due to the rarity of the subject population \& smaller # of enrolling sites, we were not able to reach accrual goals.
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-10-06
Primary completion date: 2022-11-11
Completion date: 2022-11-30
Plan to share individual participant data: NO
Clinical trial NCT02920710: ACTHAR Therapy for Central Nervous System Sarcoidosis
Official title: ACTHAR Therapy for Central Nervous System Sarcoidosis
Sponsor: The Cleveland Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Difficulty with recruitment
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-02-01
Primary completion date: 2020-11-02
Completion date: 2020-11-02
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04492618: Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis Lipoidica
Official title: Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis Lipoidica
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 12.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-09-29
Primary completion date: 2022-03-16
Completion date: 2022-03-16
Plan to share individual participant data: NO
Clinical trial NCT05048940: Efficacy, Safety, and Immunogenicity of Vaccine Reimmunization With a Third Homologous Versus Heterologous Dose Against COVID-19 in Patients Undergoing Solid Organ Transplantation.
Official title: Randomized, Open-label, Adaptive, Controlled, Phase III Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of Reimmunization With Third Dose of Homologous vs. Heterologous Vaccine Against COVID-19 in Patients Undergoing Solid Organ Transplantation: Liver, Heart, Kidney and Lung.
Acronym: REIN-TX
Sponsor: Instituto de Investigación Marqués de Valdecilla (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: The health authority indicates that the official vaccination schedule differs from that described in the protocol.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-09-01
Primary completion date: 2021-09-01
Completion date: 2021-09-01
Clinical trial NCT05663086: Immunogenicity and Safety of COVID-19 Vaccine in Population Aged 18 Years and Above
Official title: A Randomized, Blinded, Positive-controlled Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in Population Aged 18 Years and Above（Negative for Antibody Against COVID-19）
Sponsor: Guangzhou Patronus Biotech Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: According to the development of the novel coronavirus epidemic situation and the company's R\&D decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2023-01-07
Primary completion date: 2023-06-27
Completion date: 2023-06-27
Clinical trial NCT03051035: First-in-Human Study of KO-947 in Non-Hematological Malignancies
Official title: A Phase 1 First-in-Human Study of KO-947 in Locally Advanced Unresectable or Metastatic, Relapsed and/or Refractory Non-Hematological Malignancies
Sponsor: Kura Oncology, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Due to a strategic business decision Kura has stopped development of KO-947. Neither safety nor efficacy reasons were the cause of study termination.
Enrollment: 61.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-04-06
Primary completion date: 2020-06-02
Completion date: 2020-06-02
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04194034: Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer
Official title: A Dose-escalation and Phase IIa Study of TG6002 Plus Flucytosine in Patients With Unresectable Colorectal Cancer With Liver Metastases
Sponsor: Transgene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Study has been terminated after Phase I part on 23 February 2023
Enrollment: 15.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-01-17
Primary completion date: 2023-02-23
Completion date: 2023-02-23
Plan to share individual participant data: NO
Clinical trial NCT04748783: Antiviral Efficacy and Acceptability of Mouth Rinses for Inactivation of COVID-19
Official title: Antiviral Efficacy and Acceptability of Therapeutic Antiseptic Mouth Rinses for Inactivation of COVID SARS-2 Virus
Acronym: COL
Sponsor: University of North Carolina, Chapel Hill (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Funding withdrawn
Enrollment: 2.0 (ACTUAL)
Number of arms: 5.0
Start date: 2021-03-26
Primary completion date: 2021-04-07
Completion date: 2021-04-07
Baseline population: Study terminated after enrollment of only 2 participants.
Plan to share individual participant data: YES
IPD sharing description: Deidentified individual data that supports the results will be shared beginning following publication up to 1 year provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.
IPD time frame: Following publication up to 1 year
IPD access criteria: Investigator who proposes to use the data has approval from an IRB, IEC, or REB as applicable, and an executed data use/sharing agreement with UNC.
Clinical trial NCT05379322: The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients
Official title: The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients
Acronym: SYBRA
Sponsor: Abu Dhabi Stem Cells Center (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Decision of the local healthcare authority
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-07-31
Primary completion date: 2023-10-31
Completion date: 2024-04-30
Plan to share individual participant data: NO
Clinical trial NCT04523792: Virginia Opioid Treatment-Emergency Department
Official title: Virginia Opioid Treatment-Emergency Department
Acronym: VOT-ED
Sponsor: Virginia Commonwealth University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Funder has not approved protocol
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-01-01
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Clinical trial NCT04329923: The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)
Official title: The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)
Acronym: PATCH
Sponsor: University of Pennsylvania (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Cohort 1: slow accrual Cohort 2: Other studies showed no benefit Cohort 3: Study met pre-specificied futility analysis at planned second interim analysis
Enrollment: 173.0 (ACTUAL)
Number of arms: 6.0
Start date: 2020-04-09
Primary completion date: 2020-11-11
Completion date: 2020-11-13
Baseline population: All randomized patients
Limitations and caveats: Sub-study 1 was terminated early after the first interim analysis due to slow accrual Sub-study 2 was terminated early after the first 7 patients based on the recommendation of UPenn research oversight committees Sub-study 3 was terminated early due to meeting futility criteria on a pre-specified second interim analysis
Plan to share individual participant data: YES
IPD sharing description: We will publish our results in a peer-reviewed journal and make available de-identified data for additional analysis
IPD time frame: One year after study completion
IPD access criteria: Open access
Clinical trial NCT06000514: Topical Sm29 in Combination With Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis.
Official title: Association of Topical Sm29 in Gold Nanoparticles With Intravenous Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania Braziliensis: A Randomized Controlled Trial.
Sponsor: Hospital Universitário Professor Edgard Santos (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 20.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-17
Primary completion date: 2022-04-06
Completion date: 2022-07-07
Plan to share individual participant data: NO
IPD sharing description: Not to be shared.
Clinical trial NCT02674529: Study of Neural Responses Induced by Antidepressant Effects
Official title: Study of Neural Responses Induced by Simulated Antidepressants
Acronym: SONRISA
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 60.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-09-30
Primary completion date: 2021-05-31
Completion date: 2021-05-31
Plan to share individual participant data: YES
IPD sharing description: The study will follow NIMH schedule for data sharing for clinical trials. The schedule allows for descriptive data to be submitted - but not shared - ongoing and results associated with a finding - both positive and negative - to be submitted prior to the communication of a result. Once a result is communicated, either through publication and/or on the NDCT website the data specifically defined to the clinical trial will then be shared.
Clinical trial NCT04354389: DAS181 for STOP COVID-19
Official title: DAS181 for COVID-19: A Phase II Multicenter, Randomized, Placebo-Controlled, Double-Blind Study
Sponsor: Ansun Biopharma, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: No COVID-19 in EU countries - Sponsor withdraw in regulatory stage
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-07-25
Primary completion date: 2020-09-30
Completion date: 2020-11-30
Plan to share individual participant data: NO